Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 5/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 9/20 | 0.38 |
| ▸ | FLT1 | P17948 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 2/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3055165 | 0.73 | KDM5B (0.49) | PLAUKDRFLT1MEN1KMT2A | |
| SCHEMBL429755 | 0.71 | HTT (0.52) | KDRNAMPT | |
| SCHEMBL3060372 | 0.70 | KDR (0.48) | PLAUKDRFLT1 | |
| SCHEMBL1632581 | 0.68 | CYP3A4 (0.44) | MEN1KMT2AHDAC3HDAC1HDAC2 | |
| SCHEMBL448014 | 0.68 | MEN1 (0.42) | PLAUKDRMEN1KMT2AL3MBTL1 | |
| SCHEMBL429462 | 0.67 | KDR (0.71) | KDRFLT1NAMPT | |
| SCHEMBL14515126 | 0.66 | KDR (0.40) | PLAUPDE10AKDRFLT1MEN1 | |
| SCHEMBL2527507 | 0.65 | STAT6 (0.52) | PLAU | |
| SCHEMBL22261196 | 0.65 | JAK3 (0.55) | PLAUKDRMEN1KMT2AL3MBTL1 | |
| SCHEMBL429454 | 0.64 | KDR (0.73) | KDRFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642624-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-10-17 | — | — | US | disclosed |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8058445-B2 | Substituted pyridinecarboxamides for the treatment of cancer | AMGEN INC. (US) | 2011-11-15 | — | — | US | disclosed |
| EP-2311829-A1 | Substituted alkylamine derivatives and methods of use | Amgen Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| US-7687643-B2 | Process for preparing 3,3-dimethylindolines | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20060040956-A1 | Substituted alkylamine derivatives and methods of use | CHEN GUOQING | 2006-02-23 | — | — | US | disclosed |
| US-20050261313-A1 | Substituted alkylamine derivatives and methods of use | AMGEN INC. | 2005-11-24 | — | — | US | disclosed |
| US-6878714-B2 | Substituted alkylamine derivatives and methods of use | AMGEN INC. (US) | 2005-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130273004-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | PLAU 2798/4885PDE10A 1059/4885KDR 8/4885 |
| US-20050261313-A1 | Substituted alkylamine derivatives and methods of use | NAT1, PIGO, AADAC | PLAU 2519/4885PDE10A 886/4885KDR 15/4885 |
| US-20120065185-A1 | SUBSTITUTED ALKYLAMINE DERIVATIVES AND METHODS OF USE | AADAC, NAT1, PIGO | PLAU 2798/4885PDE10A 1059/4885KDR 8/4885 |
| US-20060040956-A1 | Substituted alkylamine derivatives and methods of use | AADAC, NAT1, PIGO | PLAU 2708/4885PDE10A 1092/4885KDR 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.